Skip to content

SYRA HEALTH CORP.: 10-Q filed 2026-08-11

What SYRA HEALTH CORP. reported in its quarterly report filed 2026-08-11 (fiscal Q2 2026): 37 published measures, 111 facts as tagged in accession 0001493152-26-037197.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-11
Fiscal period
fiscal Q2 2026
Accession
0001493152-26-037197 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SYRA HEALTH CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-303,829,990USD
At 2025-12-312,772,917USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-301,196,152USD
At 2025-12-31674,739USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-302,633,838USD
At 2026-03-312,362,501USD
At 2025-12-312,098,178USD
At 2025-06-302,414,163USD
At 2025-03-312,456,636USD
At 2024-12-312,878,571USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-302,123,747USD
At 2025-12-311,614,733USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30250,242USD91
2026-01-01 to 2026-06-30491,221USD181
2026-01-01 to 2026-03-31240,979USD90
2025-04-01 to 2025-06-30-63,596USD91
2025-01-01 to 2025-06-30-535,861USD181
2025-01-01 to 2025-03-31-472,265USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30643,183USD181
2025-01-01 to 2025-06-3085,754USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,394,423USD91
2026-01-01 to 2026-06-304,667,943USD181
2025-04-01 to 2025-06-301,946,199USD91
2025-01-01 to 2025-06-303,803,973USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,394,423USD91
2026-01-01 to 2026-06-304,667,943USD181
2025-04-01 to 2025-06-301,946,199USD91
2025-01-01 to 2025-06-303,803,973USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-134,169USD181
2025-01-01 to 2025-06-30-175,235USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-9,229,305USD
At 2025-12-31-9,720,526USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-3013,175,433shares91
2026-01-01 to 2026-06-3012,560,716shares181
2025-04-01 to 2025-06-3011,939,169shares91
2025-01-01 to 2025-06-3011,764,086shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-3013,551,931shares91
2026-01-01 to 2026-06-3012,937,216shares181
2025-04-01 to 2025-06-3011,939,169shares91
2025-01-01 to 2025-06-3011,764,086shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-300.02USD/shares91
2026-01-01 to 2026-06-300.04USD/shares181
2025-04-01 to 2025-06-30-0.01USD/shares91
2025-01-01 to 2025-06-30-0.05USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-300.02USD/shares91
2026-01-01 to 2026-06-300.04USD/shares181
2025-04-01 to 2025-06-30-0.01USD/shares91
2025-01-01 to 2025-06-30-0.05USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-305,192USD
At 2025-12-316,986USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-3044,439USD181
2025-01-01 to 2025-06-3054,067USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30251,571USD91
2026-01-01 to 2026-06-30442,554USD181
2025-04-01 to 2025-06-30-63,158USD91
2025-01-01 to 2025-06-30-536,492USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-303,747,154USD
At 2025-12-312,738,530USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-301,196,152USD
At 2025-12-31674,739USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-06-301,470,023USD
At 2025-12-31918,374USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-30814,732USD91
2026-01-01 to 2026-06-301,595,004USD181
2025-04-01 to 2025-06-30816,053USD91
2025-01-01 to 2025-06-301,878,543USD181

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,066,303USD91
2026-01-01 to 2026-06-302,037,558USD181
2025-04-01 to 2025-06-30752,895USD91
2025-01-01 to 2025-06-301,342,051USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2026-04-01 to 2026-06-30236,485USD91
2026-01-01 to 2026-06-30449,532USD181
2025-04-01 to 2025-06-30289,070USD91
2025-01-01 to 2025-06-30576,357USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-3047,351USD91
2026-01-01 to 2026-06-3054,272USD181
2025-04-01 to 2025-06-3029,712USD91
2025-01-01 to 2025-06-3066,885USD181

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-302,123,747USD
At 2025-12-311,614,733USD
At 2025-06-302,305,924USD
At 2024-12-312,395,405USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-3011,848,954USD
At 2025-12-3111,806,765USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-06-3077,644USD
At 2025-12-3127,401USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-06-3077,644USD
At 2025-12-3127,401USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2026-06-30148,826USD
At 2025-12-31147,032USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-30220,333USD
At 2025-12-31194,821USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-30153,384USD
At 2025-12-31205,423USD

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-04-01 to 2026-06-30741USD91
2026-01-01 to 2026-06-301,795USD181
2025-04-01 to 2025-06-305,978USD91
2025-01-01 to 2025-06-3012,775USD181

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,217USD91
2026-01-01 to 2026-06-304,679USD181
2025-04-01 to 2025-06-303,858USD91
2025-01-01 to 2025-06-307,087USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-1,329USD91
2026-01-01 to 2026-06-3048,667USD181
2025-04-01 to 2025-06-30-438USD91
2025-01-01 to 2025-06-30631USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-06-304,679USD181
2025-01-01 to 2025-06-307,087USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-06-3014,800USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30551,649USD181
2025-01-01 to 2025-06-30205,534USD181

Inspect the source

Entity
SYRA HEALTH CORP. / CIK 0001922335
Captured
2026-09-21T17:41:11.939Z
SEC response SHA-256
b7deb50e336dc97b3dc95be11b8ad17619851faa670b1bd5b706682829760083

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001922335.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))